dr. bekaii-saab on the use of regorafenib in patients with mcrc
Published 6 years ago • 111 plays • Length 1:20Download video MP4
Download video MP3
Similar videos
-
1:21
dr. bekaii-saab discusses regorafenib use in mcrc
-
1:16
dr. bekaii-saab on tas-102 and regorafenib in mcrc
-
0:20
copy of dr. bekaii-saab on tas-102 and regorafenib in mcrc
-
1:39
dr. bekaii-saab on dosing strategies with regorafenib in crc
-
0:46
copy of dr. bekaii-saab discusses regorafenib use in mcrc
-
1:32
dr. bekaii-saab discusses qol with regorafenib dose escalation in mcrc
-
2:26
dr. bekaii-saab on the impact of regorafenib in crc
-
0:57
dr. bekaii-saab discusses the next steps with regorafenib in crc
-
19:12
covid-19 and the lab leak
-
16:35
dr. finn on regorafenib for the treatment for patients with hcc
-
1:32:16
demystifying medicine 2016: the intestinal microbiome and inflammatory bowel disease
-
0:28
tanios bekaii-saab, md: reinitiating regorafenib in patients with mcrc
-
1:46
dr. udit verma on regorafenib in patients with mcrc
-
2:24
dr. bekaii saab compares toxicities of regorafenib and tas-102 in colorectal cancer
-
2:27
dr. bekaii-saab on the redos study in metastatic colorectal cancer
-
1:23
dr. bekaii-saab on benefits associated with regorafenib or tas-102 for crc
-
0:42
dr. bendell on the future of regorafenib for patients with crc
-
11:24
managing toxicities associated with regorafenib
-
1:20
tanios bekaii-saab, md: clinical data supporting regorafenib in mcrc
-
1:12
tanios bekaii-saab, md: mechanisms of action in regorafenib
-
1:27
tanios bekaii-saab, md, comments on dosing regorafenib (stivarga) in 3rd line treatment of mcrc
-
1:33
dr. bekaii saab on the expansion of treatment options in colorectal cancer